5 Pharmaceutical Stocks to Buy According to Brandon Haley’s Holocene Advisors

4. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Holocene Advisors’ Stake Value: $124.8 million

Percentage of Holocene Advisors’ 13F Portfolio: 0.67%

Number of Hedge Fund Holders: 40

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is another leading pharmaceutical and biotechnology company on the list. It is headquartered in Massachusetts, US. It is primarily focused on developing RNA interference therapeutics for genetic diseases. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) posted a Q3 revenue of 2021 at $187.6 million. It missed the analyst estimates for EPS by -$0.15, coming up with an EPS at -$1.72.

Holocene Advisors stake in the company comprises over 0.6 million shares in the third quarter of 2021. This is after the hedge fund increased its stake by 20% in the company in the same quarter. However, the leading stakeholder in the company is the hedge fund Casdin Capital with a total of 1 million shares in the company in the third quarter. 

On November 22, Needham analyst Joseph Stringer raised the price target on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to $205 from $180 and kept a ‘Buy’ rating on the shares.